The QualityStocks Daily Wednesday, November 15th, 2023

Today's Top 3 Investment Newsletters

SmallCapRelations(CISO) $0.1600 +67.36%

MarketClub Analysis(BLLB) $0.0020 +42.86%

CryptoCurrencyWire(BLQC) $0.0864 +40.26%

The QualityStocks Daily Stock List

Netlist, Inc. (NLST)

Greenbackers, QualityStocks, OTCPicks, StreetInsider, HotOTC, CoolPennyStocks, StockEgg, BullRally, PennyTrader Publisher, MarketBeat, StockRich, PennyStockVille, PennyInvest, MarketClub Analysis, MadPennyStocks, CRWEWallStreet, Stock Rich, Wall Street Resources, TopPennyStockMovers, Marketbeat.com, MicrocapVoice, Momentum Traders, Stock Traders Chat, StockMarketWatch, StockOodles, The Street, BUYINS.NET, TradersPro, Trading Concepts, Wyatt Investment Research, DrStockPick, Penny Sleuth, CRWEPicks, CRWEFinance, BestOtc, Penny Invest, SmallCapNetwork, AllPennyStocks, PennyOmega, StockHotTips, PennyToBuck, PennyTrader, Penny Stock Rumble, Stockpalooza, Dividend Opportunities, StockMister, The Momentum Traders Network, Top Stock Picks, Dynamic Wealth Report, TradingMarkets, INO Market Report, Wise Alerts, Barchart, Alternative Energy, TopStockAnalysts, Stock Fortune Teller, PennyStocks24, SmarTrend Newsletters, InvestorGuide, Investors Alley, SmallCapVoice, SmallCapReview, PoliticsAndMyPortfolio, MarketWatch, MicroCapINPLAY, Momentum Trades, Zacks and Hit and Run Candle Sticks reported earlier on Netlist, Inc. (NLST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Netlist, Inc. (OTCQB: NLST) (LON: 0K6M) is a company focused on designing, manufacturing and marketing memory subsystems for the serve, high-performance computing and communications markets.

The firm has its headquarters in Irvine, California and was incorporated in June 2000 by Christopher Lopes, Chun Ki Hong and Jayesh Bhakta. It operates as part of the tech hardware and semiconductors industry, under the semiconductors industry, in the technology sector. The firm serves consumers around the globe, with a focus on those in the United States.

The enterprise’s offerings include a storage-class memory product known as HybriDIMM, which unifies dynamic random-access memory (DRAM) and NAND flash in a plug-and-play module delivering terabyte storage capacities operating at nanosecond memory speeds. It also offers nonvolatile (NV) memory products, such as NVvault DDR4 NVDIMM that provides data acceleration and protection in a joint electron device engineering council standard DDR4 interface; and specialty DIMMs and embedded flash products for use in data center and industrial applications. It resells component products, including DRAM, solid state drive (SSDs) and NAND flash products to storage customers, appliance customers, system builders, and cloud and data center customers. This is in addition to selling component inventory to distributors and other users of memory integrated circuits. The enterprise markets and sells its products through a direct sales force and a network of independent sales representatives.

The company’s latest financial results show increases in its sales, with its CEO noting that they remained focused on executing on its product and licensing strategies. This will help meet consumer needs while also generating additional revenues for the company.

Netlist, Inc. (NLST), closed Wednesday's trading session at $1.45, up 29.4643%, on 1,252,950 volume. The average volume for the last 3 months is 425,810 and the stock's 52-week low/high is $0.8701/$6.10.

Gamer Pakistan (GPAK)

We reported earlier on Gamer Pakistan (GPAK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gamer Pakistan Inc. (NASDAQ: GPAK) is an e-sports event promotion and product marketing firm that is focused on creating inter-university, college and professional e-sports events for both men’s and women’s teams, primarily e-sports opportunities with universities and colleges.

The firm has its headquarters in Henderson, Nevada and was incorporated in 2021. It operates as part of the specialty business services industry, under the industrials sector. The firm primarily serves consumers in Pakistan.

The company intends to integrate competitive events that include its teams and leagues with regional and global teams and leagues sponsored by others, including firms formed by its stockholders, to promote sports, including esports, in other countries. The company carries out its operations in Pakistan through Elite Sports Pakistan Pvt. Ltd. (ESP) and K2 Gamer (PVT) Ltd (K2 Gamer). ESP has entered into 119 agreements with universities and sports authorities in Pakistan and been granted exclusive rights to license, produce, distribute and monetize a range of sports events for inter-collegiate competition. The company also intends to expand the range of its esports offerings to other markets.

The enterprise has thus far organized and held approximately 30 separate championships, including the first Annual University Esports National Tournament and Championship in Pakistan. In December 2022, it also held the week-long inaugural National Esports Free Fire Championship.

The company, which is set to give an update on its operations soon, remains focused on establishing a strong presence in the esports ecosystem of Pakistan and realizing its vision of becoming the premier destination for students in Pakistan. This may in turn positively influence shareholder value as well as the company’s overall growth.

Gamer Pakistan (GPAK), closed Wednesday's trading session at $0.6044, up 0.548994%, on 52,440 volume. The average volume for the last 3 months is 3,840 and the stock's 52-week low/high is $0.5789/$4.39.

FLYHT Aerospace Solutions (FLYLF)

QualityStocks and MarketBeat reported earlier on FLYHT Aerospace Solutions (FLYLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Flyht Aerospace Solutions Ltd (OTCQX: FLYLF) (CVE: FLY) is a company engaged in the provision of real-time communications with aircrafts for the aerospace industry.

The firm has its headquarters in Calgary, Canada and was incorporated in 1998, on September 17th. Prior to its name change in May 2012, the firm was known as AeroMechanical Services Limited. It operates as part of the aerospace and defense industry, under the industrials sector. The firm serves consumers around the globe, with a focus on those in the United States, Asia, Mexico, Africa, China, South/Central America, the Middle East, Australia, Canada and Europe.

The enterprise’s offerings include FLYHT-WVSS-II, a mounted aircraft sensor that detects and reports water vapor; TAMDAR, a tropospheric airborne meteorological data reporting system that delivers airborne weather and humidity data in real-time; and AFIRS, an automated flight information reporting system that is an aircraft satcom/interface device which enables cockpit voice communications, real-time aircraft state analysis, and the transmission of aircraft data while inflight. It also provides AFIRS Edge, which offers AID functions to supply aircraft's data to the flight deck for EFB applications; ClearPort, which offers a clear view into the status of an aircraft; FuelSense, which provides insight to an airline's management and usage of fuel; and FleetWatch, which provides a configurable fleet situational awareness platform.

The company recently announced its latest financial results, with its CEO noting that they remained focused on increasing profitability, improving efficiency and making progress on their main strategic growth initiatives. This may positively influence investments into the company as well as shareholder value.

FLYHT Aerospace Solutions (FLYLF), closed Wednesday's trading session at $0.524, off by 1.1321%, on 16,306 volume. The average volume for the last 3 months is 1,474 and the stock's 52-week low/high is $0.4591/$0.88031.

Bionoid Pharma (BINP)

We reported earlier on Bionoid Pharma (BINP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bionoid Pharma Inc. (OTC: BINP) is a hemp cultivation and medical production firm involved in the hemp cultivation business.

The firm has its headquarters in Beverly Hills, California and was incorporated in 1997, on October 20th. Prior to its name change, the firm was known as Bronya International Corporation. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers across the globe.

The company focuses on large-scale, ecologically sustainable hemp cultivation through farming partnerships in Latin America; and on pharmaceutical-grade processing of high-quality, low-cost cannabinoids as the foundation of their global cannabis business. It has licensed operations in the United States, Ecuador and Canada.

The enterprise is focused on pharmaceutical research, laboratory testing, volume extraction, and product development of CBD products. It has developed and commercialized a platform dubbed the muscle pattern recognition (MPR), a clinical tool for the analysis of muscle function in patients presenting with back pain. MPR offers information regarding muscle recruitment patterns in patients suffering from neck and back pain that can help healthcare professionals in the evaluation and treatment of neck and back injuries and illnesses.

The firm, which has future plans to expand operations to include the large, emerging Asian market, recently signed an exclusive license agreement with Global Alerts Corp., a move that allows for cost-effective mass message distribution via existing mobile network, eliminates human error and reduces training demands. This may also open the firm up to new growth and investment opportunities and create new avenues to generate value for its shareholders.

Bionoid Pharma (BINP), closed Wednesday's trading session at $1, even for the day. The average volume for the last 3 months is 15,539 and the stock's 52-week low/high is $0.03999/$1.25.

Nubeva Technologies (NBVAF)

We reported earlier on Nubeva Technologies (NBVAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nubeva Technologies Ltd (OTCQB: NBVAF) (CVE: NBVA) is a company focused on the development and licensing of software-based decryption solutions and TLS (SSL) network decryption solutions, including Ransomware Reversal.

The firm has its headquarters in San Jose, California and was incorporated in 2016. It operates as part of the software-infrastructure industry, under the technology sector. The firm serves consumers in the United States.

The company enables deep packet inspection for cybersecurity and application monitoring systems and services. It solves the growing visibility, performance, and complexity gaps introduced by the evolution of TLS, newer networks and application architectures, and the continuous scaling of network traffic. The company generates revenue from the provision of cloud-based security software and services, as well as professional services associated with customizing its products. Software revenue includes licenses derived from software and software services.

The enterprise’s TLS solution comprises of a micro-endpoint agent that automatically discovers and extracts symmetric keys from handshake processes in memory, in real time, and then security forwards them to the decryption systems for fast and easy decryption. The solution works without any modification to applications, libraries, network and systems architectures, or PKI. Its session key intercept (SKI) works on nearly all versions of Linux, containers and Kubernetes, and Windows server/client systems. The solution enables decryption of TLS1.3, 1.2 with PFS, as well as pinned certificate sessions for both passive and inline use cases. The enterprise delivers the solution as a software toolkit to enable solution and service providers, as well as mature SecOps/DevOps teams in the enhancement of existing or new visibility solutions.

The firm was recently granted a patent for its capability to decrypt TLS traffic with certificate pinning, a move that solidifies its unique position in the market but also plays a crucial role in safeguarding the firm’s intellectual property.

Nubeva Technologies (NBVAF), closed Wednesday's trading session at $0.397, even for the day. The average volume for the last 3 months is 320,146 and the stock's 52-week low/high is $0.1883/$1.54.

MeiraGTx (MGTX)

MarketBeat, StreetInsider, StockMarketWatch, MarketClub Analysis, InvestorPlace, InsiderTrades and Early Bird reported earlier on MeiraGTx (MGTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MeiraGTx Holdings PLC (NASDAQ: MGTX) (FRA: 328) is a clinical-stage gene therapy firm focused on the development of treatments for patients with a range of severe illnesses.

The firm has its headquarters in New York and was incorporated in 2015, on March 20th. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe. Geographically, it operates in the United States, the United Kingdom and the European Union.

The company is party to a research collaboration agreement with Janssen Pharmaceuticals Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. It focuses on 3 distinct areas of unmet medical need; ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases.

The enterprise has 6 programs in clinical development and a pipeline of preclinical and research programs. Its product pipeline is comprised of Botaretigene Sparoparvovec, a formulation developed to treat X-Linked Retinitis Pigmentosa Associated with Mutations in the RPGR Gene; AAV-AIPL1 for the Treatment of LCA4; and AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy. It also develops AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy; AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy; and AAV-hAQP1 for the Treatment of Radiation-Induced Grade 2/3 Xerostomia.

The firm remains committed to actively pursuing strategic partnerships following its $30 million strategic investment from Sanofi. This will bolster the firm’s overall growth while also encouraging additional investments into the company.

MeiraGTx (MGTX), closed Wednesday's trading session at $4.95, up 2.2727%, on 126,443 volume. The average volume for the last 3 months is 24.066M and the stock's 52-week low/high is $3.49/$8.77.

Tilray Brands Inc. (TLRY)

InvestorPlace, Schaeffer's, StocksEarning, The Street, StockEarnings, MarketClub Analysis, MarketBeat, QualityStocks, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CFN Media Group, CNBC Breaking News, Early Bird, The Street Report, Daily Profit, INO Market Report, StreetAuthority Daily, Inside Trading, The Rich Investor, Tip.us, Top Pros' Top Picks, FreeRealTime, InvestmentHouse, Trading For Keeps, Trading Concepts, Eagle Financial Publications, InvestorsObserver Team, Investors Alley, Investment House, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TheTradingReport, The Night Owl, StrategicTechInvestor, Money Morning, Rick Saddler, InvestorsUnderground, AllPennyStocks, MarketClub, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

For several decades, the federal government’s categorization of marijuana as a Schedule I controlled substance has prompted the FDA to assess various applications from researchers looking to create therapeutic drugs derived from the plant. The FDA recently published two documents that reflect on more than 50 years of exploring marijuana-based drugs and offer insights into the potential future of drug development.

The documents highlight the evolution of the FDA’s evaluations regarding marijuana-related drugs and products and also discuss the exploration of different consumption methods, such as edibles, and delve into the examination of lesser-known cannabinoids and additional components like terpenes.

Throughout the past half century, the FDA has reviewed more than 800 investigational new drug (IND) applications linked to marijuana and marijuana-derived products. This extensive period witnessed significant changes in the forms of cannabis products, societal perspectives, and the legal framework surrounding cannabis, all of which have influenced the FDA’s stance.

Initially, there were only a few applications after the Controlled Substances Act (CSA) passage in 1970. However, in recent years, especially as more states have legalized cannabis for medical and recreational use, there has been a substantial surge in applications. In the last decade alone, the number of marijuana-related drug applications nearly equaled those from the preceding 40 years combined. Presently, the FDA is reviewing more than 150 active INDs concerning marijuana-based drugs and related synthetics.

The FDA has adapted its guidance for researchers and drug developers venturing into the realm of cannabis. It released a guidance document on botanical drug development in 2016 and, earlier this year, provided separate guidance on the distinctive considerations surrounding cannabis and hemp.

The INDs have mainly focused on four key clinical areas over the years, predominantly centered around addiction and pain medicine (53%), followed by neurology (19%), immunology and inflammation (14%) and ending with psychiatry (9%).

The evolution of product forms has also been substantial. Initially, in the 1970s, most INDs revolved around smokable marijuana. Yet, as the landscape shifted with state-level legalization, the FDA began receiving more applications concerning vapor, oral and infused food products such as sweets and baked goods. This transition in product forms, according to the FDA, is largely due to changes in consumer preferences, which are moving from exclusively smoking dried marijuana flowers to consuming alternative forms such as edibles.

Despite these transformations, challenges persist in developing marijuana-related drugs for clinical trials, particularly concerning the safety of unknown compounds. Nonetheless, the broadening exploration of different form factors aligns with recent drug approvals such as Syndros (2016) and Epidiolex (2018), both oral formulations.

The FDA anticipates increased interest in clinical research regarding marijuana-based drugs, envisioning a focus on new products, diverse forms and lesser-known components such as terpenes. However, challenges remain due to the Schedule I status of marijuana, hindering extensive research into its properties.

Nora Volkow, director of the National Institute on Drug Abuse (NIDA), has repeatedly emphasized that marijuana’s Schedule I classification significantly hampers research due to administrative hurdles. The federal prohibition on cannabis has also impeded research efforts, as noted by other federal agencies such as the National Center for Complementary and Integrative Health.

Change is, however, slowly underway. The DEA recently ended a long-standing monopoly on domestic cannabis manufacturing for research purposes and is streamlining access to marijuana for scientists after a marijuana research bill’s enactment last year. Additionally, the DEA is reviewing marijuana’s scheduling status following a recommendation from the Department of Health and Human Services (HHS) to reclassify it from Schedule I to Schedule III.

Once this reclassification is completed, cannabis industry players such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) could see an easing of some of the hurdles they have been facing in their bid to bring innovative products to the market.

Tilray Brands Inc. (TLRY), closed Wednesday's trading session at $1.82, up 5.2023%, on 17,859,794 volume. The average volume for the last 3 months is 8.27M and the stock's 52-week low/high is $1.50/$5.12.

Coinbase Global Inc. (COIN)

Schaeffer's, InvestorPlace, The Street, Prfmonline, MarketClub Analysis, Greenbackers, QualityStocks, MarketBeat, INO Market Report, Kiplinger Today, Investopedia, Zacks, OTCPicks, SmallCapVoice, Ceocast News, The Online Investor, Early Bird, CoolPennyStocks, HotOTC, Daily Trade Alert, StockEgg, InsiderTrades, Trades Of The Day, Stock Stars, Penny Invest, Stock Rich, StocksEarning, The Wealth Report, Top Pros' Top Picks, The Stock Psycho, Top Gun, CNBC Breaking News, StockEarnings, BestOtc, Wealth Daily, HotShotStocks, StockHotTips, BullRally, PennyStockVille, MadPennyStocks, FeedBlitz, Energy and Capital, Smartmoneytrading, Summa Money, PennyInvest, StockRich, PennyTrader Publisher, Profit Confidential, Stockpalooza, CryptoCurrencyWire, Today's Financial News, Eagle Financial Publications, AlphaShark Trading, bullseyeoptiontrading, Atomic Trades, Blaque Capital Stocks, Pennybuster, Dynamic Wealth Report, BloomMoney, Dawn Report, CRWEWallStreet, Cabot Wealth, Standout Stocks, wyatt research newsletter, WiseAlerts, wealthmintrplus, Wealth Whisperer, TipRanks, StockMister, Stock Traders Chat, Penny Stock Finder, Stock Analyzer, Early Investing, Round Up the Bulls, Penny Stock Rumble, AllPennyStocks, Momentum Traders, MicrocapVoice, Louis Navellier, Green Chip Stocks and Stock Fortune Teller reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The recent surge in the cryptocurrency market dubbed the “uptober” rally has captured considerable attention. Bitcoin, a major player, has witnessed an impressive 35% increase since October, with assets such as SOL and LINK experiencing even more substantial gains. However, delving beyond the surface, it becomes apparent that understanding liquidity trends is crucial for comprehending the underlying dynamics of this price surge, offering valuable insights into the current market cycle and potential future developments.

A crucial insight, emphasized earlier this year by CoinDesk, is the impact of trading volumes on price stability. Low volumes indicate little market activity at particular price points, which could result in higher price volatility and less market depth. Conversely, greater trade volumes signify increased market participation, forging a firmer consensus and offering a more stable basis for price changes.

An intriguing development is the recovery in trade volumes for ether and Bitcoin, key liquidity metrics. Notably, some of the highest trading volume days in the last two years coincided with this recent rally. This surge in activity contrasts with previous low volumes, hinting at a shift in market dynamics.

Digging deeper, the analysis extends to futures open interest for Bitcoin and ether, which have surpassed $20 billion for the first time since the FTX collapse last year. This surge is primarily attributed to institutional capital, with the CME gaining market share and positioning itself as a formidable bitcoin futures exchange.

Options, another facet of liquidity, also exhibit significant growth. Bitcoin options’ open interest recently reached a new high, surpassing $16 billion. However, the increase in futures trading adds intrinsic leverage to the system, which might increase the chance that forced liquidations will impact market movements.

Despite the strong price increases over the past few months, order book depth analysis, another liquidity metric, shows a tightening trend. Data from CoinDesk shows a 1% depth of book for Bitcoin and ether, indicating a decline and depicting fewer sellers than buyers.

Using a seven-day lookback time to calculate annualized realized volatility for ether and Bitcoin reveals a recent spike in volatility. Nevertheless, it is still very low compared to the previous bull market in 2020 and 2021. Volatility-adjusted spot volumes for Bitcoin are currently in the top quartile of the 2020–2021 bull market cycle.

The combination of these elements — which includes a market with comparatively few sellers, increased but still manageable volatility, and increased interest from conventional institutional investors — indicates that the market may be moving into a new phase. Looking ahead, this recovery may signal the start of the next bull market, even though short-term corrections and a gloomy macro environment are still possible.

Industry analysts are likely to keep an eye on exchanges such as Coinbase Global Inc. (NASDAQ: COIN) to track how the recent trading activity pans out over the coming weeks and months.

Coinbase Global Inc. (COIN), closed Wednesday's trading session at $98.15, up 6.5805%, on 11,968,933 volume. The average volume for the last 3 months is 36.489M and the stock's 52-week low/high is $31.55/$114.43.

Rivian Automotive Inc. (RIVN)

InvestorPlace, Schaeffer's, Kiplinger Today, The Street, QualityStocks, MarketClub Analysis, MarketBeat, INO Market Report, Early Bird, Investopedia, StockEarnings, The Online Investor, Zacks, Daily Trade Alert, Trades Of The Day, StocksEarning, TipRanks, The Night Owl, Louis Navellier, InvestorIntel, AllPennyStocks, DividendStocks, InvestorsUnderground, Top Pros’ Top Picks, Top Pros' Top Picks, Cabot Wealth and bullseyeoptiontrading reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The China Passenger Car Association has revealed that Chinese startup Li Auto outsold Tesla in its local market last month. While Tesla sells fully electric cars in China, limiting itself to consumers who are only interested in electric cars, Li Auto sells hybrid SUVs equipped with a fuel tank to charge the battery.

This likely contributed to the startup selling a record 40,422 vehicles last month, far more than the 28,626 battery electric cars (BEVs) sold in October. Range anxiety is a major barrier to electric vehicle adoption in most EV markets, even in China, which has the widest network of public charging stations (almost 1.8 million as of 2022). Equipping its electric cars with a fuel tank for additional power likely alleviated some consumers’ concerns about range.

Li Auto projects similar vehicle sales numbers through the fourth quarter this year, forecasting around 41,700 to 42,600 vehicles per month. The startup said that it plans to begin selling its first-ever battery electric vehicle (BEV), the MEGA multipurpose vehicle in February 2024 followed by the launch of three more battery-only electric vehicles in the second half of 2024.

The startup far outsold Tesla in October despite offering higher purchase prices than both the Model Y and Model 3. Tesla has been engaged in a fierce discount battle in the increasingly competitive Chinese market, but it seems customers are still flocking to local automakers despite relatively higher prices.

However, it is still unclear whether Li Auto’s high October sales numbers were merely a fluke or whether the startup will continue to outsell Tesla in the Chinese market. Data from the China Passenger Car Association shows that the Beijing, China-based startup sold 36,060 cars in September while Tesla sold 43,507 vehicles.

China is without a doubt the world’s largest electric vehicle market and contributes to around one-fifth of Tesla’s total sales. Tesla reported its first dip in earnings and revenue since Q3 2019 in October amid poor global economic conditions and high interest rates that CEO Elon Musk said would impact the company’s market base.

Increased competition from Chinese vehicle startups and automakers with millions of dollars in government funding has also pushed Tesla into a corner in its largest market and forced it to consistently slash prices to remain competitive. In the meantime, Li Auto is planning on more than doubling the size of its research and development team to fast-track the development of autonomous driving technology.

As the competition for market share heats up, manufacturers such as Rivian Automotive Inc. (NASDAQ: RIVN) will have to keep improving their offerings in order to corner a bigger segment of the market for themselves.

Rivian Automotive Inc. (RIVN), closed Wednesday's trading session at $17.24, up 2.0118%, on 52,207,487 volume. The average volume for the last 3 months is 344,084 and the stock's 52-week low/high is $11.68/$35.735.

Compass Minerals International Inc. (CMP)

SmarTrend Newsletters, QualityStocks, MarketBeat, The Online Investor, Daily Trade Alert, Trades Of The Day, DividendStocks, Marketbeat.com, The Street, InvestorPlace, Kiplinger Today, MiningNewsWire, Zacks, StreetAuthority Daily, Schaeffer's, StreetInsider, All about trends, MarketClub Analysis, The Stock Dork, Insider Wealth Alert, Top Pros' Top Picks, Daily Wealth, Wyatt Investment Research, Daily Market Beat, CRWEFinance, BUYINS.NET and Barchart reported earlier on Compass Minerals International Inc. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DTN’s price tracker for the retail price of fertilizer in the United States shows that the price has continued to increase, as seen in the last week of last month. DTN collects price bids of fertilizer from agriculture retailers weekly to compile its fertilizer index. Figures show that in comparison to September, the prices of six of the eight major fertilizers were higher. This includes UAN32, which hit $415 per ton and UAN28, which reached $358 per ton. MAP also saw its price reach $801 per ton, DAP averaged at $713/ton and 10-34-0 got to $611/ton.

Of all the increases, however, only one fertilizer saw a 5% increase: anhydrous. This nitrogen fertilizer recorded an average price of $826 per ton for the month of October. The tracker also recorded a drop in the price of urea and potash fertilizers, which averaged at $573 per ton and $508 a ton respectively.

On a price per pound of nitrogen basis, the average price of UAN32 was $0.65, UAN28 hit $0.64, urea got to $0.62 and anhydrous reached $0.50.

Bruno Fonseca, Rabobank’s senior analyst of farm inputs, stated in the latest issue of the semiannual fertilizer outlook by RaboResearch Food and Agribusiness that the fertilizer market was calmer, especially in comparison to last year.  The models in the report demonstrate recovery in the usage of fertilizer globally thus far into the year, with a 3% increase. This is a positive sign, especially since usage declined by about 7% in the previous year. Forecasts expect that by 2024, fertilizer usage will have gone up by an additional 5%.

The report also highlighted that figures included aligned with the Affordability Index, which demonstrated improved conditions for fertilizer purchase, compared to 2022.

It is expected that nutrients will face certain challenges next year, with the report noting that the nitrogen market may struggle with a drop in demand from wheat and corn growers. Uncertainty in the production cost of nitrogen fertilizers and related uncertainty in the natural gas market is also expected.

Some things are looking up, however, such as the outlook for potash and phosphates. It is expected that supply will increase in the potash market as well as in the phosphate market, with the latter increase brought on by the return of DAP/MAP exports from China.

Currently, the prices of all fertilizers are lower in comparison to 2022 figures, with anhydrous, potash, both UAN28 and UAN32, urea, DAP, 10-34-0 and MAP all being cheaper by 42%, 41%, 39%, 31%, 23%, 20% and 18% respectively.

Fertilizer makers such as Compass Minerals International Inc. (NYSE: CMP) now have to continually streamline their supply chains in order to keep costs down and avail fertilizers at affordable prices so that food prices don’t skyrocket beyond their current levels.

Compass Minerals International Inc. (CMP), closed Wednesday's trading session at $25.85, up 2.6608%, on 251,282 volume. The average volume for the last 3 months is 140,882 and the stock's 52-week low/high is $23.3618/$47.68.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, StockEarnings, Penny Dreamers, InvestorPlace, CFN Media Group, bullseyeoptiontrading and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed a supplement related to certain restrictions on resale that will apply to the Celly Nu shares that will be distributed to the FSD Pharma securityholders. The company filed the supplement, dated Nov. 15, 2023, as an addition to the Management Information Circular that was filed last month; the company noted that capitalized terms not defined in this news release have the meanings assigned in the circular. The supplement was filed in connection with the company’s upcoming special meeting, which is scheduled for Nov. 20, 2023. “The chair of the meeting has the discretion to accept proxies received less than 48 hours prior to the meeting and, to ensure that FSD Pharma securityholders have sufficient time to vote, FSD Pharma will now accept proxies received prior to 5:00 p.m. (Toronto time) on Friday, Nov. 17, 2023,” the announcement stated. “FSD Pharma securityholders who have already submitted a proxy or voting instruction form and do not wish to change their vote, do not need to take any further action with respect to the meeting.”

To view the full press release, visit https://ibn.fm/SGWdw

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD is also focused on the research and development of UNBUZZD(TM), a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. FSD maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information about the company, please visit www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Wednesday's trading session at $1.16, up 6.422%, on 64,803 volume. The average volume for the last 3 months is 500,906 and the stock's 52-week low/high is $0.6181/$2.10.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, Dynamic Wealth Report, StreetInsider, MarketClub Analysis, Small Caps, Uncommon Wisdom, Marketbeat.com, CRWEWallStreet, PennyToBuck, CRWEPicks, InsiderTrades, CRWEFinance, BestOtc, DrStockPick, PennyOmega, Schaeffer's, StockHotTips, TraderPower, Awareness Stocks, StockOodles, Street Insider, The Street, TopPennyStockMovers, Broad Street and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics have been subject to significantly increased attention from the medical and scientific communities in recent years due to claims of their medical efficacy against various mental health conditions. While a majority of psychedelic compounds are still illegal at the federal level and in most states, increasingly promising findings have resulted in at least 100 conferences on psychedelic research and medicine in the United States alone over the past three years.

The main agenda at these events has been how psychedelics and psychedelic-assisted psychotherapy can aid in the treatment of conditions such as anxiety, depression and post-traumatic stress disorder (PTSD).

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are also poised to approve the use of certain psychedelics in therapeutic settings in the next couple of years, with the FDA issuing a new draft guidance on psychedelic trials in late June. The draft guidance advised researchers on how to construct psychedelic studies to determine their potential as treatments for psychiatric conditions.

While the medical and scientific communities were happy that the FDA was taking action regarding psychedelic research, language regarding the necessity of psychological support during psychedelic therapy has sparked a fierce debate. The FDA’s draft guidance encouraged study sponsors to justify the necessity of psychological support during and after psychedelic administration. Furthermore, it urged sponsors to describe trial design elements that would help reduce potential bias or “quantify the contribution of psychotherapy to the overall treatment effect.”

The regulatory agency’s reservations about psychotherapy come from the belief that it could complicate evaluations of the efficacy of therapeutic psychedelic compounds as well as the labeling of psychedelic treatments. Studies on psychedelic-assisted therapy have found that the talk therapy aspect of the treatment is crucial during the integration stage where patients learn to integrate any realizations and epiphanies they may have made during a guided psychedelic trip.

Some critics say the FDA’s draft guidance on psychedelic trials doesn’t fully understand the role psychological support plays in psychedelic treatments. Many scientists and academics within the psychedelic research space believe that the talk therapy aspect is critical to the success of psychedelic therapy. Additionally, most psychedelic facilitators and practitioners would say that building a rapport between patient and guide is key to optimizing psychedelic treatment outcomes.

Consequently, altering aftercare protocols or eliminating talk therapy entirely would likely reduce patient response rates and limit the treatment’s efficacy.

Tea Petkova, an IFS-trained psychedelic facilitator and holder of a master’s degree in applied cognitive neuroscience says going through the processes of preparation, expansion and integration with one facilitator builds the trust patients need to follow their facilitators’ guidance throughout treatment. Ethically, testing the efficacy of psychedelic treatments without the talk-therapy component should happen on patients with no mental-health diagnoses, Petkova says.

Unfortunately, most of the patients who take part in psychedelic-related studies tend to have diagnoses for one or more mental-health disorders for which they receive psychological support. Limiting their access to psychological support or changing facilitators during treatment could consequently limit the long-term benefits of psychedelic treatments.

Startups that have made significant strides in developing psychedelic medicines such as atai Life Sciences N.V. (NASDAQ: ATAI) may have to give the FDA feedback regarding the best way to leverage psychological support during psychedelic-assisted therapy.

atai Life Sciences N.V. (ATAI), closed Wednesday's trading session at $1.2, off by 4.3825%, on 631,081 volume. The average volume for the last 3 months is 271,030 and the stock's 52-week low/high is $1.05/$3.65.

The QualityStocks Company Corner

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

Turbo Energy (NASDAQ: TURB), a leader in photovoltaic energy storage, was featured in an interview with Proactive London after the Spain-based company completed its Nasdaq listing in the U.S. Turbo Energy's General Manager Mariano Soria joined Thomas Warner from Proactive to provide an overview of the business, describing it as being "at the forefront of technology for storing photovoltaic energy" and explaining how the company is utilizing artificial intelligence to help improve its offering. He shares how the company uses AI to help its customers save money by analyzing energy usage patterns and cross-referencing the data with weather and energy-price forecasts to maximize efficient deployment of stored energy. Soria further explains that the learning done by the company over the last ten years has gone into its primary product, called the SunBox — a plug-and-play solution that can be installed in a user's home very quickly and with minimal training. He also discusses plans for the future, saying that he is expecting explosive growth given that Turbo Energy has "probably the most advanced system for cost-savings in residential photovoltaics."

To view the full interview, visit https://ibn.fm/C6GDc

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.

Products

Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

Inverters

The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Wednesday's trading session at $1.42, off by 3.4014%, on 17,521 volume. The average volume for the last 3 months is 291 and the stock's 52-week low/high is $1.19/$7.90.

Recent News

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Diamond Lake Minerals (OTC: DLMI), which specializes in the development and support of digital assets and SEC-registered security tokens, was featured on Benzinga's All-Access. Diamond Lake's CEO Brian Esposito joined the program to discuss his vision for the company and DLMI's "old-school" approach to running a business: focusing on the balance sheet, increasing profits and wealth enhancement. "I've been honored to take over as CEO of Diamond Lake Minerals in August. What we are doing is bridging the traditional securities market with the future of digital securities. So, I'd like to look at us like an old school General Electric conglomerate model. Our intentions are a highly covered subsidiary, industry agnostic across all different companies and industries. It is strictly focused on bringing in revenues, sharing those revenues and earnings with shareholders and truly focused on balance sheets, increasing profitability," Esposito explained. "But the beautiful thing about what we're building here and what I've been doing over the last 10 years with digital assets and working in regulated environments such as security tokens is incorporating within those business units with the idea of security token offerings. So, I do believe we truly have the hybrid approach of bringing in all that generational wealth that's on the sidelines that hear about things like crypto… tokens… NFTs and digital assets… They don't know how to get involved... They're intimidated by it. They don't know how to go and get a digital wallet. With all these friction points, what I believe that we're creating here is that missing piece to get them involved in this wonderful market with something that they're familiar with and that's going on their Charles Schwab account, calling their broker and buying a stock that's operating in this industry."

To view the full article and interview, visit https://ibn.fm/uusNH and https://ibn.fm/Ozuuy

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

  • Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
  • Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
  • Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
  • Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
  • Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
  • IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
  • Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
  • Technology: DLMI plans to back pioneers driving the next tech revolution.
  • Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
  • Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
  • Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
  • Education: DLMI collaborates with platforms revolutionizing learning through tech.
  • Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
  • Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
  • TV: DLMI intends stakes in TV platforms innovating content delivery.
  • Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
  • Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
  • Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
  • IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
  • Data Management: DLMI seeks ventures optimizing data utilization and insights.
  • Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
  • Streaming: DLMI intends to back streaming platforms prioritizing user experience.
  • Real World Assets: DLMI eyes investments translating tangible assets into digital value.
  • Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
  • Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
  • Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
  • Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
  • Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
  • Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
  • Studio Production: DLMI’s vision includes support for studios transforming content creation.
  • Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
  • Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
  • Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
  • Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
  • Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
  • Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
  • Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
  • Space Economy: DLMI targets investments in ventures monetizing space exploration.
  • Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
  • Financial Technology: DLMI seeks partnerships modernizing financial transactions.
  • Gaming: DLMI aims to back game developers enhancing user immersion.
  • Travel: DLMI eyes collaborations transforming travel experiences through tech.
  • Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
  • Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
  • AI: DLMI seeks to support AI innovations humanizing tech interactions.
  • Esports: DLMI targets investments in platforms amplifying esports experiences.
  • Construction: DLMI plans to back ventures modernizing construction practices.
  • Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
  • Retail Tech: DLMI envisions collaborations digitizing retail experiences.
  • Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Wednesday's trading session at $3.9, up 15.3846%, on 614 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.90/$.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive business update along with its financial results for the third quarter ended September 30, 2023.

Key Updates and Achievements

Successfully concluded a crucial FDA Type-B meeting, gathering vital guidance for the NDA submission of PAX-101. This milestone showcases significant progress in PaxMedica's developmental journey, potentially resulting in substantial time and cost savings.

Completed the final PAX-101 Phase III trials for Human African Trypanosomiasis (HAT), marking a significant milestone in our research and development efforts.

Strategically acquired suramin research assets from Rediscovery Life Sciences (RLS), a crucial step in expediting the New Drug Application (NDA) submission process for PAX-101.

Successfully completed commercial-scale development plan for PAX-101. On track for manufacturing API validation, drug product validation, and registration lots in Q1 2024.

Howard Weisman, Chief Executive Officer of PaxMedica, commented, "The accomplishments in the third quarter of 2023 represent significant progress in our journey towards a 2024 US FDA filing of an NDA for the treatment of HAT with PAX-101 (IV suramin). The favorable results from our retrospective HAT-301 study reinforce the substantial benefits of suramin in treating this life-threatening infection. With these milestones, PaxMedica is well-positioned to expand our research initiatives, including the exploration of PAX-101 for addressing the core symptoms of Autism Spectrum Disorder."

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Wednesday's trading session at $2.42, up 11.5207%, on 1,286,176 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.6545/$69.19.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, 2023; the company also noted upcoming milestones. Notable financial numbers from the report include net loss for Q3 totaled approximately $4.5 million compared to an estimated $3.4 million for the comparable period in 2022; R&D expenses came in at $3.4 million for the third quarter compared to approximately $2.2 million for the comparable period in 2022; and general and administrative expense reached approximately $1.1 million. CNS reported cash of approximately $0.9 million with an additional $2.6 million in a warrant inducement transaction and placements on the ATM facility.

Operationally, the company noted that enrollment numbers rose to 239 participants in the ongoing potentially pivotal study of Berubicin for treatment of GBM, with expected full enrollment by next month; topline data from preplanned interim analysis from the Berubicin study is also expected next month. "Over the course of 2023, we have demonstrated solid execution and rapid progression of enrollment in our ongoing potentially pivotal study of Berubicin," said CNS Pharmaceuticals CEO John Climaco in the press release. "We are preparing for the most significant milestones for patients, the company and our stockholders in just a few short weeks. . . . With topline data from our interim analysis expected in the coming weeks, we are poised to determine whether or not the independent Data Safety Monitoring Board recommends continuing the study. We are hopeful that by the end of this study, Berubicin will ultimately demonstrate life-saving value as a second-line treatment for patients with recurrent glioblastoma. We look forward to an exciting remainder of the year and building value for all stakeholders in the near and long-term."

To view the full press release, visit https://ibn.fm/wS56A

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.92, up 14.9701%, on 62,929 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$6.597.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous clinical trials, DehydraTECH-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks. "That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit," a recent article quotes Lexaria CEO Chris Bunka as saying. "This success has been replicated in other studies, most notably diabetes. In Lexaria's pre-clinical diabetes study, DIAB-A22-1, conducted in obese diabetic-conditioned animals, DehydraTECH-CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, in addition to triglyceride and blood urea nitrogen levels… Lexaria's DehydraTECH has also proven its superiority and advantage over traditional oral delivery methods in the nicotine replacement market… ‘Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world's leading existing brands,' noted Mr. Bunka."

To view the full article, visit https://cnw.fm/PMphs

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $1.34, up 3.0769%, on 17,915 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488/$3.5953.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave (NYSE: QBTS) is a leader in quantum computing systems, software and services and the world's first commercial supplier of quantum computers. The company has announced important research results that demonstrate successful Quantum Error Mitigation ("QEM") in its Advantage2(TM) annealing quantum computing experimental prototype. According to the announcement, the techniques reduce errors in quantum simulations, producing results consistent with the quantum system maintaining its quantum state ("coherence") for an order of magnitude longer time than an unmitigated system. D-Wave expects to leverage these techniques to drive performance advancements in the forthcoming Advantage2 system and future processors.

"Errors represent the most significant obstacle in all forms of quantum computation," said Mohammad Amin, fellow, quantum algorithms and systems, who led the research at D-Wave. "This work demonstrates the successful mitigation of such errors in quantum annealing, producing measurement results as if the qubits were nearly one order of magnitude more coherent. This enables computation in regimes that were previously inaccessible, such as quantum simulations of exotic magnetic materials, an important milestone on the road to demonstrating quantum supremacy on D-Wave processors."

To view the full article, visit https://ibn.fm/iMLY2

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $0.8943, up 9.061%, on 1,895,131 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3962/$3.20.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore, a company engaged in the exploration for plus separation and scalable production of REEs, just announced a technical update on its RapidSX(TM) Demonstration Plant in Kingston, Ontario

Mike Schrider, the company's VP and COO, lauded this milestone, noting how it ultimately led to optimizing the chemistry delivery and feedback systems to and from the RapidSX(TM) platform within the plant

These steps will lead the way to demo plant commercialization, scale-up, and technology transfer, for its developing 7,500 tonnes per annum (ex-cerium and ex-yttrium) REE separation plant – the Louisiana Strategic Metals Complex ("LA-SMC") in Alexandria, Louisiana

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the exploration for rare earth elements ("REEs") in Canada and the U.S., as well as the associated development of superior separation and scalable production technologies, just announced a technical update on its important RapidSX(TM) Demonstration Plant in Kingston, Ontario. The update marks a significant milestone for the company, and will allow them to "discreetly quantify the previous qualitative attributes of the RapidSX(TM) technology platform and the resulting rare earth element products" (https://ibn.fm/3HrKh).

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX™, for separating and purifying critical metals. Ucore intends to deploy this technology in pursuit of a CM supply chain independent of China for Western original equipment manufacturers (“OEMs”), most notably in the automotive and renewable energy industries.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. Its initial focus is on processing heavy and light rare earth elements (“REEs”), disrupting a supply chain that is dominated by China.

China currently controls about 80% of the world’s access to REE mining projects and over 90% of the world’s REE processing capabilities, and it produces about 95% of the goods containing REE components.

 

Ucore is working to scale Western supply needs by establishing REE separation and rare earth oxide (“REO”) production capabilities in cooperation with strategic upstream supply and downstream offtake partnerships. The company, along with its industry partners, aims to unlock access to Western REEs for current consumer, energy, manufacturing and military sectors.

By 2025, Ucore expects to commercially separate U.S.-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets (“REPMs”) – the essential component of electric motors and generators required to support the world’s transition to electrification and sustainable energy sources.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

The company has three initial U.S.-friendly feedstock agreements in place for the Louisiana complex, along with multiple developing offtake agreements. It received a C$16 million+ incentive package offer from Louisiana Economic Development to support construction of the SMC.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Wednesday's trading session at $0.4823, up 0.145349%, on 50,063 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.395/$1.15.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Multiple sclerosis is a chronic illness that affects an individual's brain and spinal cord, resulting in problems moving one's arms or legs, issues with vision, and problems with balance or sensation.  While the cause of this disease is still not known, researchers theorize that it may be caused by the immune system of an individual attacking its own tissues. Estimates show that roughly 2.8 million individuals around the globe live with this illness. The disease's symptoms often get worse as time goes by, which lowers the quality of life of some patients. Dr. Ari J. Green, cosenior author of a recent study's cosenior author, theorizes that progression of disability in patients with multiple sclerosis is likely brought on by the effect of the loss of axons and connections from important circuits that underlie crucial neurological functions. The advancements being made in detecting MS symptom progression could be a great complement to the promising treatments for this condition being developed by enterprises such as Clene Inc. (NASDAQ: CLNN).

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Wednesday's trading session at $0.441, up 0.8%, on 218,382 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3576/$1.99.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom's wholly owned subsidiary, Leaders in Community Alternatives, Inc. ("LCA"), recently won a new contract to supply alcohol monitoring technologies and services in California

The contract is valued at up to $3 million over the initial 3-year term, based on anticipated usage estimates

Since 2003, LCA has provided continuous transdermal alcohol monitoring ("CAM") programs for thousands of California drivers found driving under the influence ("DUI")

The alcohol monitoring programs use tamper-proof tags worn around the ankle to measure the amount of alcohol in an offender's body by taking a sample of their sweat every 30 minutes

SuperCom's reputation for providing reliable and high-quality electronic monitoring services was pivotal in securing the new contract, President and CEO Ordan Trabelsi said

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions, provides advanced safety, identification, connectivity, and security products and solutions to governments as well as public and private organizations around the world. The Tel Aviv, Israel-headquartered company wholly owns several active subsidiaries, including, among others, Leaders in Community Alternatives, Inc. ("LCA").

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Wednesday's trading session at $0.425, up 1.1905%, on 2,569,468 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3416/$2.695.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. According to the announcement, the reverse stock split will become effective at 4:01 p.m., Eastern Time, on Nov. 16, 2023. The company's common stock will continue to trade on the Nasdaq Capital Market under the symbol SNES and will begin trading on a split-adjusted basis when the market opens on Nov. 17, 2023. At a special meeting held on Aug. 18, 2023, the company's stockholders granted the company's board of directors the discretion to effect a reverse stock split of the company's common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-12, with such ratio to be determined by the board.

To view the full press release, visit https://ibn.fm/qA1Rj

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Wednesday's trading session at $0.181, up 1.7998%, on 1,746,429 volume. The average volume for the last 3 months is 411,105 and the stock's 52-week low/high is $0.175/$7.718.

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0).

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a leading Swiss hosted secure and private communications platform, today announced the launch of its SekurRelay Enterprise Email Solution, allowing corporate executives and management to "split" their company email domain. This enables companies to benefit from SekurMail's SekurSend/SekurReply feature and other Swiss-hosted privacy and security solutions SekurMail offers without having to migrate all employees, eliminating a huge roadblock to mass adoption of SekurMail by large corporations and government agencies. "We are excited to provide SekurRelay to our customers as it provides protection from BEC attacks to C-level executives and managers who traditionally send highly sensitive emails inside and outside of their organizations," said Alain Ghiai, CEO of Sekur Private Data. "We have had many instances where a company wanted to keep their existing email provider for convenience for most of their employees, but wanted to have their C levels use Sekur, while keeping the same company or government domain email. This feature cannot come soon enough, as we read constantly about banks, large organizations, law enforcement agencies and governments being compromised in their email. Fortunately, we can offer the only Swiss-hosted, proprietary, private and secure communications platform that does not rely on big tech infrastructure, open-source coding or data mining, therefore reducing exponentially the risk of cyber penetration. Our prime directive is to provide private and secure communications for everyone, and as we are not connected to any big tech platform, we offer a truly independent, private and secure means of communications, without any data mining, through our proprietary technology and our secure servers based in Switzerland."

To view the full press release, visit https://ibn.fm/oBvON

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Wednesday's trading session at $0.0536, up 6.4548%, on 232,659 volume. The average volume for the last 3 months is 157,941 and the stock's 52-week low/high is $0.027/$0.1576.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, was featured in an interview with Proactive, where its CEO Charlie Fernandez joined host Steve Darling to provide an update on the company's latest financial results. NextPlat has made impressive strides in consolidating its global e-commerce and Progressive Care health care operations, leading to significant growth. During the interview, Fernandez highlighted the company's strong financial performance in the third quarter, reporting consolidated revenues of $15.3 million. This represents a remarkable >481% increase compared to the third quarter of the previous year. In addition, the company's gross margins saw substantial improvement, reaching 30% for the quarter ending on Sept. 30, 2023, up from the previously reported 26%. These financial results demonstrate NextPlat's effective consolidation efforts and its ability to drive revenue and improve profitability. The company is well positioned to build on its success and deliver value to its stakeholders as it continues to expand its operations and explore new opportunities in the e-commerce and health care sectors.

To view the full article, visit https://ibn.fm/5Dxqj

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Wednesday's trading session at $1.9081, off by 6.922%, on 24,661 volume. The average volume for the last 3 months is 13,660 and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .